

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren, et al.

Examiner: Chernyshev, O.

Serial No.: 09/813,463

Group Art Unit: 1653

Filed: March 20, 2001

Docket: 098810/027 8740

For: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS**

STATEMENT UNDER 37 C.F.R. § 1.821 (f) and (g)

Commissioner of Patents
Washington, D.C. 20231

Sir:


In connection with the Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. The paper copy of the Sequence Listing, submitted in accordance with 37 CFR 1.825(b), is the same as the computer readable copy of the Sequence Listing; and
2. The content of the Sequence Listing information recorded in computer readable form is identical to the paper copy of the Sequence, submitted in accordance with 37 C.F.R. § 1.825(a), does not include any new matter.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 12-1-03


Robert M. Bedgood
Reg. No. 43,488

PILLSBURY WINTHROP LLP
11682 EL CAMINO REAL, SUITE 200
SAN DIEGO, CA 92130

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being mailed with the United States Postal Services on the date shown below in an envelope addressed to the United States Patent and Trademark Office, Attn: Box Sequence, P.O. Box 1450, Mail Stop Sequence Listing, Alexandria, VA 22313-1450

Dated: 12/1/03By: Pate Murray